News round-up for 17-21 March by DDW Senior Digital Content Editor Diana Spencer.

This week the DDW news round-up takes a look at developments in cancer research, including AZ’s acquisition of EsoBiotec, positive trial results for an allogeneic T-cell therapy, and a new drug target for glioblastoma.

The top stories:

AstraZeneca acquires in vivo cell therapy developer

EsoBiotec, a biotechnology company developing in vivo cell therapies, is to be acquired by AstraZeneca.

Read more…

Allogeneic T-cell therapy doubles rate of survival free from GvHD

Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies.

Read more…

Study identifies new therapeutic target for glioblastoma

Scientists have demonstrated that glioblastoma (GBM) tumour stem cells became less able to proliferate and invade tissues when the production of the prion protein was blocked, highlighting a potential new therapeutic target.

Read more…

Promising drug candidates for previously ‘undruggable’ cancer target

Reportedly for the first time, researchers from the University of Bath have identified  promising  drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it.

Read more…